Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Kairos presents positive preclinical outcomes of anti-tumor therapies at AACR IO

Kairos Pharma (NYSE:KAPA) announced the presentation of positive preclinical data on its investigational compounds KROS 101 and KROS 401 during the American Association for Cancer Research and Immuno-Oncology (ACCR IO)...

February 26, 2025

Developments

Alligator reports encouraging OS for mitazalimab in metastatic pancreatic cancer

Alligator Bioscience (STO:ATORX) has announced updated results from its Phase 2 OPTIMIZE-1 study evaluating mitazalimab in combination with chemotherapy as a first-line treatment for metastatic pancreatic cancer...

February 26, 2025

Executive Moves

Andrew Gengos joins Terns as CFO

Terns Pharmaceuticals (NASDAQ:TERN) has announced the appointment of Andrew Gengos as chief financial officer (CFO), effective immediately. Mr. Gengos brings 25 years of leadership experience in life sciences and...

February 25, 2025

Developments

IP highlights Istesso’s Phase 2b study findings of leramistat in RA

IP Group (LSE:IPO) has reported that Instesso has provided its shareholders with the results of its 12-week randomized, double-blind, placebo controlled Phase 2b study of leramistat in patients with moderate-to-severe...

February 25, 2025

Developments

First patient dosed in Aim’s Phase 2 study of Ampligen and Imfinzi in pancreatic cancer

AIM ImmunoTech (NYSE American:AIM) announced that the first new patient has been dosed in the Phase 2 study of its Ampligen and Astra Zeneca’s anti-PD-L1 immune checkpoint inhibitor, Imfinzi, as a potential combination...

February 25, 2025

Developments

OSE Reports Phase 2 results for Lusvertikimab in UC presented at ECCO

OSE Immunotherapeutics (ISIN:FR0012127173; Mnemo:OSE) has announced that full efficacy and safety data from the induction period of the randomized, double-blind, placebo-controlled, Phase 2 CoTikiS study of...

February 24, 2025

Developments

PepGen reveals positive initial Phase 1 study results of PGN-EDODM1 in DM1

PepGen (NASDAQ:PEPG) has announced initial positive data from the five and ten mg/kg dose cohorts in its ongoing FREEDOM-DM1 Phase 1 study investigating PGN-EDODM1 in myotonic dystrophy type 1 (DM1). PeoGen reports that...

February 24, 2025

Developments

USPTO grants OS NOA covering manufacturing of OST-HER2

OS Therapies (NYSE-A:OSTX) has announced that it has received a notice of allowance from the US Patent & Trademark Office (USPTO) covering the manufacturing methods required for OST-HER2. According to OS, the USPTO...

February 20, 2025

Developments

Hemostemix Licences CytoImmune’s BioReactor Technologies

Hemostemix (TSXV:HEM; OTCQB:HMTXF) has announced that it has secured an arm’s length perpetual, royalty-free global license to CytoImmune’s BioReactor stem cell technologies. Subject to the TSXV Exchange acceptance...

February 20, 2025

Developments

FDA fast tracks BioRestorative’s BRTX-100 in cLDD

BioRestorative Therapies (NASDAQ:BRTX) has announced that the FDA has granted Fast Track designation to the BRTX-100 stem cell program for the treatment of chronic lumbar disc disease (cLDD). “We are thrilled that the...

February 20, 2025

Developments

MOBILion showcases new mass spectrometry approach at US HUPO conference

Closely held MOBILion Systems has announced its participation in the 21st annual US HUPO conference this month in Philadelphia. The company will showcase its new Parallel Accumulation with Mobility Aligned Fragmentation...

February 19, 2025

Developments

AHN launches Ekso Bionics’ transformational robotic exoskeleton technology

Non-profit Allegheny Health Network (AHN) has introduced the groundbreaking EksoNR, a wearable, full-body robotic exoskeleton that assists patients recovering from neurological injury or disease. The weight-bearing...

February 19, 2025

Subscribe